KRX Growth Companies With High Insider Ownership For August 2024

The South Korea stock market on Thursday halted its two-day winning streak, shedding 11.68 points or 0.45 percent to finish at 2,556.73, amid mixed performances across various sectors. As the KOSPI navigates these fluctuations, identifying growth companies with high insider ownership can be crucial for investors looking to leverage potential rebounds and sustained performance in a volatile market environment.

Top 10 Growth Companies With High Insider Ownership In South Korea

Name	Insider Ownership	Earnings Growth
People & Technology (KOSDAQ:A137400)	16.5%	35%
Fine M-TecLTD (KOSDAQ:A441270)	17.2%	36.4%
Bioneer (KOSDAQ:A064550)	17.5%	89.7%
Global Tax Free (KOSDAQ:A204620)	18.1%	90.6%
Seojin SystemLtd (KOSDAQ:A178320)	29.6%	58.7%
Park Systems (KOSDAQ:A140860)	33%	36.6%
Vuno (KOSDAQ:A338220)	19.5%	105%
HANA Micron (KOSDAQ:A067310)	20%	97.4%
UTI (KOSDAQ:A179900)	33.1%	122.7%
Techwing (KOSDAQ:A089030)	18.7%	77.8%

Click here to see the full list of 86 stocks from our Fast Growing KRX Companies With High Insider Ownership screener.

Let's take a closer look at a couple of our picks from the screened companies.

ALTEOGEN (KOSDAQ:A196170)

Simply Wall St Growth Rating: ★★★★★★

Overview: ALTEOGEN Inc., a biotechnology company, specializes in creating long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars with a market cap of ₩16.04 trillion.

Operations: The company's revenue segment primarily comprises biotechnology, generating ₩121.09 billion.

Insider Ownership: 26.6%

Return On Equity Forecast: 45% (2027 estimate)

ALTEOGEN, a South Korean biotech firm, recently received MFDS approval for Tergase®, a high-purity recombinant hyaluronidase. This milestone supports its transition to a commercial-stage company. The firm's earnings are forecasted to grow significantly at 72.95% per year, with revenue expected to increase by 48.7% annually—outpacing the market average. Despite recent shareholder dilution and share price volatility, ALTEOGEN trades significantly below its estimated fair value and maintains high insider ownership.

• Click here and access our complete growth analysis report to understand the dynamics of ALTEOGEN.
• Our comprehensive valuation report raises the possibility that ALTEOGEN is priced higher than what may be justified by its financials.

CLASSYS (KOSDAQ:A214150)

Simply Wall St Growth Rating: ★★★★★☆

Overview: CLASSYS Inc. is a global provider of medical aesthetics devices with a market cap of ₩3.20 billion.

Operations: The company generates revenue primarily from its Surgical & Medical Equipment segment, which amounted to ₩191.53 million.

Insider Ownership: 10.1%

Return On Equity Forecast: 28% (2027 estimate)

CLASSYS Inc., a South Korean firm specializing in medical aesthetics, is trading 25.5% below its estimated fair value. The company's earnings and revenue are forecasted to grow at 22.84% and 21.2% per year, respectively, outpacing the market average for revenue growth. Despite no significant insider trading activity in the past three months, CLASSYS maintains high insider ownership and has consistently grown earnings by 25.9% annually over the past five years.

• Click to explore a detailed breakdown of our findings in CLASSYS' earnings growth report.
• The analysis detailed in our CLASSYS valuation report hints at an inflated share price compared to its estimated value.

PharmaResearch (KOSDAQ:A214450)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: PharmaResearch Co., Ltd., along with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea and has a market cap of ₩1.78 trillion.

Operations: PharmaResearch's revenue from its pharmaceuticals segment is ₩280.29 billion.

Insider Ownership: 39%

Return On Equity Forecast: 22% (2027 estimate)

PharmaResearch, a South Korean pharmaceutical company, is trading 44.3% below its estimated fair value with earnings forecasted to grow 20.74% annually over the next three years. Despite high insider ownership and no significant insider trading in the past three months, its revenue growth rate of 19.8% per year lags behind market expectations (28%). The company's earnings grew by 55.4% last year but have shown high share price volatility recently.

• Dive into the specifics of PharmaResearch here with our thorough growth forecast report.
• Upon reviewing our latest valuation report, PharmaResearch's share price might be too pessimistic.

Key Takeaways

• Unlock more gems! Our Fast Growing KRX Companies With High Insider Ownership screener has unearthed 83 more companies for you to explore.Click here to unveil our expertly curated list of 86 Fast Growing KRX Companies With High Insider Ownership.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com